Clinical trials: Cystic Fibrosis
CFTR-RD
Assessment of Patients Not Concluded After Neonatal Screening of Cystic Fibrosis.
Assessment of the outcome of patients not concluded fir cystic fibrosis, either symptomatic patients or asymptomatic children detected by newborn screening for cystic fibrosis.
- Trial name
- NCT06300567
- Testing
- data collection
- Volunteers
- 400 people
- Sponsor
- Hôpital Necker-Enfants Malades
Cystic Fibrosis
Lum-Iva-biota: Exploring the Respiratory Mycobiota and Microbiota Profile in French CF Patients Taking Lumacaftor-Ivacaftor
n2015, VERTEX company - producing already KALYDECO (IVACAFTOR, VX-770) potentiator molecule that is recommended for the treatment of CF patients aged ≥ 6 y, with CFTR mutation altering the channel regulation (class III mutations)…
- Trial name
- Lum-Iva-Biota (NCT03565692)
- Testing
- the lung mycobiota and microbiota profile, the gut mycobiota and microbiota profile
- Where
- 8 sites in France
- Volunteers
- 250 people
- Sponsor
- University Hospital, Bordeaux
Cystic Fibrosis
Small Circulating RNA as Molecular Markers of Lung Disease in Cystic Fibrosis
The aim of our study is to assess miRNAs expression profiles in the circuling blood of patients with cystic fibrosis and highlight "signatures" that could reflect the pulmonary status of patients
- Trial name
- MIRDIAMUCO (NCT02992080)
- Testing
- miRNAs isolation from blood samples of patients and control
- Where
- 2 sites in France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis
Muco Smartphone Exacerbation
Exacerbation in cystic fibrosis play an important role in terms of mortality and morbidity. Exacerbation frequencies is relatedto FEV1 decline and mortality.
- Trial name
- MUSE (NCT02122289)
- Testing
- Application of Smartphone, No application Smartphone
- Where
- 2 sites in France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Montpellier
Cystic Fibrosis
COVID-19 Antibody Responses in Cystic Fibrosis
Coronavirus disease 2019 (COVID-19) which is caused by the virus SARS-CoV-2 has resulted in an ongoing global pandemic. It is unclear whether the relatively low number of reported cases of COVID-19 in people with CF (pwCF) is due…
- Trial name
- CAR-CF (NCT05052294)
- Where
- 2 sites in Czechia
- Volunteers
- 50 people
- Sponsor
- University Hospital, Motol
Cystic Fibrosis in Children
Response to CFTR Modulators in CF Patients Under 18 Years
CFTR modulators should improve the prognosis of Cystic Fibrosis. Identifying patients under the age of 18 responding to CFTR modulators as well as detecting possible toxicity is an important medical objective given the potential…
- Trial name
- MODUL-CF (NCT04301856)
- Testing
- CFTR Modulators
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Societe Francaise de la Mucoviscidose
Cystic Fibrosis, Venous Thrombosis
Cystic Fibrosis and Totally Implantable Vascular Access Devices
The purpose of this study is to evaluate the incidence of venous thrombosis occurring on totally implantable vascular access devices in cystic fibrosis patients who need a new device (it can be the first one or a subsequent one)…
- Trial name
- RITHM (NCT00244270)
- Testing
- totally implantable vascular access device
- Volunteers
- 97 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients due to cystic fibrosis receiving the treatment with LipaCreon in order to evaluate the…
- Conditions
- Cystic Fibrosis, Exocrine Pancreatic Insufficiency, Pancreatic Diseases, Digestive System Diseases
- Trial name
- NCT01427712
- Testing
- Pancrelipase
- Where
- 21 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Mylan Inc.
Cystic Fibrosis
Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis
The investigators know that adherence to medications in children with cystic fibrosis (CF) is poor. Forgetfulness has often been reported as a barrier to adherence by both CF patients and their parents.
- Trial name
- NCT02301377
- Testing
- Spiro PD personal spirometer
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan
Cystic Fibrosis, Nontuberculous Mycobacterial Pulmonary Infection
Prospective Healthcare-Associated Links in Transmission of Nontuberculous Mycobacteria
Pulmonary NTM infection is recognized as one of the most challenging infections to treat among people with cystic fibrosis (PwCF), notable for prolonged treatment courses and often poor response to therapy.
- Trial name
- pHALT NTM (NCT05686837)
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of North Carolina, Chapel Hill
Digestive System Diseases, Pancreatic Disease
Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients
Hypothesis:DCI 1020 capsules are safe and effective in treating exocrine pancreatic insufficiency in CF patients <= 2 years of age.
- Conditions
- Digestive System Diseases, Pancreatic Disease, Cystic Fibrosis, Exocrine Pancreatic Insufficiency
- Trial name
- NCT00663975
- Testing
- DCI 1020
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Digestive Care, Inc.
Cystic Fibrosis
Technology-enabled Patient Support System for Self-management of CF
This project will test a technology-enabled patient support system (PSS) as a self-management tool for children with CF and their family caregivers.
- Trial name
- NCT03910881
- Testing
- Open-platform patient support system (PSS) app
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis
Infant Study of Inhaled Saline in Cystic Fibrosis
The purpose of this study is to assess whether 7% hypertonic saline (HS) is an effective and safe therapy in infants and young children with CF.
- Trial name
- ISIS (NCT00709280)
- Testing
- 7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
- Where
- 30 sites in United States, Canada
- Volunteers
- 321 people
- Sponsor
- CF Therapeutics Development Network Coordinating Center
Cystic Fibrosis, Atypical Mycobacterium Infection
Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients
OBJECTIVES: I. Determine the prevalence of nontuberculous mycobacteria in sputum cultures from patients with cystic fibrosis. II. Compare the clinical course of patients with negative versus positive cultures.
- Trial name
- NCT00004296
- Volunteers
- 1,000 people
- Sponsor
- National Center for Research Resources (NCRR)
Cystic Fibrosis
Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients
The purpose of this study is to determine the effect of 24 weeks of treatment with BIIL 284 BS compared with placebo on pulmonary function and incidence of pulmonary exacerbation in adult and pediatric cystic fibrosis patients.
- Trial name
- NCT00060801
- Testing
- BIIL 283 BS (Amelubent)
- Where
- 35 sites in United States
- Volunteers
- 420 people
- Sponsor
- Boehringer Ingelheim
Cystic Fibrosis, Healthy Subjects
Evaluation of Nebulization and Positive Expiratory Pressure Combination
The purpose of this study is to compare the efficiency of nebulization and positive expiratory pressure combination
- Trial name
- NCT02535130
- Testing
- Positive expiratory pressure, amikacine nebulization
- Where
- Belgium
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cystic Fibrosis
Evaluation of New Device for Beta-adrenergic Sweat Test in the Context of Stratification of Patient With Cystic Fibrosis
This is a clinical study to evaluate a new medical system used to perform a sweat secretion-based test for the diagnosis of cystic fibrosis.
- Trial name
- BESTRACYFIC (NCT06836453)
- Testing
- Sweat stimulation and secretion quantification
- Where
- Belgium
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cystic Fibrosis
Choline Nutrition in Children With Cystic Fibrosis
Cystic fibrosis (CF) is the most common lethal, inherited disorder among Caucasians. Choline is an essential vitamin and as a methyl donor is critically needed to support the normal metabolism.
- Trial name
- NCT01070446
- Testing
- Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1
- Where
- Canada
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Cystic Fibrosis, Pancreatic Insufficiency
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
The primary objective of this study is to determine if PANCRECARB® MS-16 (pancrelipase) is safe and effective in reducing steatorrhea (as measured by 72-hour stool fat determinations) in children and adults with cystic fibrosis…
- Trial name
- NCT00432861
- Testing
- PANCRECARB® (pancrelipase)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Digestive Care, Inc.
Cystic Fibrosis (CF), Cystic Fibrosis Pulmonary Exacerbation
Identifying the Causes and Risk Factors of Pulmonary Exacerbations in Cystic Fibrosis
The CF-Tracker study is a community surveillance study, designed to understand the causes of exacerbations in people with cystic fibrosis (CF) (pwCF).
- Trial name
- CF-Tracker (NCT06940531)
- Where
- 18 sites in United Kingdom
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Alexander Horsley